This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To develop a diagnostic test that stratifies epileptic seizures (ES) from psychogenic nonepileptic seizures (PNES) by developing a multimodal algorithm that integrates plasma concentrations of selected immune response–associated proteins and patient clinical risk factors for seizure.
Methods Daily blood samples were collected from patients evaluated in the epilepsy monitoring unit within 24 hours after EEG confirmed ES or PNES and plasma was isolated. Levels of 51 candidate plasma proteins were quantified using an automated, multiplexed, sandwich ELISA and then integrated and analyzed using our diagnostic algorithm.
Results A 51-protein multiplexed ELISA panel was used to determine the plasma concentrations of patients with ES, patients with PNES, and healthy controls. A combination of protein concentrations, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), intercellular adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein-2 (MCP-2), and tumor necrosis factor–receptor 1 (TNF-R1) indicated a probability that a patient recently experienced a seizure, with TRAIL and ICAM-1 levels higher in PNES than ES and MCP-2 and TNF-R1 levels higher in ES than PNES. The diagnostic algorithm yielded an area under the receiver operating characteristic curve (AUC) of 0.94 ± 0.07, sensitivity of 82.6% (95% confidence interval [CI] 62.9–93.0), and specificity of 91.6% (95% CI 74.2–97.7). Expanding the diagnostic algorithm to include previously identified PNES risk factors enhanced diagnostic performance, with AUC of 0.97 ± 0.05, sensitivity of 91.3% (95% CI 73.2–97.6), and specificity of 95.8% (95% CI 79.8–99.3).
Conclusions These 4 plasma proteins could provide a rapid, cost-effective, and accurate blood-based diagnostic test to confirm recent ES or PNES.
Classification of Evidence This study provides Class III evidence that variable levels of 4 plasma proteins, when analyzed by a diagnostic algorithm, can distinguish PNES from ES with sensitivity of 82.6% and specificity of 91.6%.
Glossary
- AED=
- antiepileptic drug;
- AIC=
- Akaike information criterion;
- AUC=
- area under the receiver operating characteristic curve;
- CI=
- confidence interval;
- CRP=
- C-reactive protein;
- DT=
- decision tree;
- EMU=
- epilepsy monitoring unit;
- ES=
- epileptic seizures;
- HC=
- healthy control;
- ICAM-1=
- intercellular adhesion molecule 1;
- IFN=
- interferon;
- IL=
- interleukin;
- KNN=
- K nearest neighbor;
- LAR=
- legally authorized representative;
- LR=
- logistic regression;
- M-CSF=
- macrophage colony-stimulating factor;
- MCP=
- monocyte chemoattractant protein;
- MIP=
- macrophage inflammatory protein;
- MMP=
- matrix metalloproteinase;
- MSD=
- Meso Scale Discovery;
- NB=
- naive Bayes;
- NSAID=
- nonsteroidal anti-inflammatory drug;
- PNES=
- psychogenic nonepileptic seizures;
- RF=
- random forest;
- ROC=
- receiver operating characteristic;
- SCF=
- stem cell factor;
- TNF-R1=
- tumor necrosis factor–receptor 1;
- TNF-R2=
- tumor necrosis factor–receptor 2;
- TRAIL=
- tumor necrosis factor–related apoptosis-inducing ligand
Footnotes
Go to Neurology.org/Nhttps://n.neurology.org/lookup/doi/10.1212/WNL.0000000000011552 for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 467
Class of Evidence: NPub.org/coe
- Received December 8, 2019.
- Accepted in final form November 20, 2020.
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
